EQ VS AZN Stock Comparison
Performance
EQ10/100
10/100
EQ returned -70.89% in the last 12 months. Based on SPY's performance of -16.09%, its performance is below average giving it a score of 10 of 100.
AZN100/100
100/100
AZN returned 6.03% in the last 12 months. Based on SPY's performance of -21.20%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
EQ100/100
100/100
2 analysts offer 12-month price targets for EQ. Together, they have an average target of 0, the most optimistic target put EQ at 0 within 12-months and the most pessimistic has EQ at 0.
AZN85/100
85/100
5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79.
Sentiment
EQ72/100
72/100
EQ had a bullish sentiment score of 71.71% across Twitter and StockTwits over the last 12 months. It had an average of 4.25 posts, 3.92 comments, and 7.17 likes per day.
AZN70/100
70/100
AZN had a bullish sentiment score of 70.02% across Twitter and StockTwits over the last 12 months. It had an average of 101.58 posts, 140.17 comments, and 324.32 likes per day.
Technicals
EQ10/100
10/100
EQ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
AZN11/100
11/100
AZN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
EQ10/100
10/100
EQ has missed earnings 8 times in the last 20 quarters.
AZN56/100
56/100
AZN has missed earnings 3 times in the last 20 quarters.
Profit
EQ10/100
10/100
Out of the last 20 quarters, EQ has had 1 profitable quarters and has increased their profits year over year on 1 of them.
AZN77/100
77/100
Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
EQ34/100
34/100
EQ has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.
AZN48/100
48/100
AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Equillium, Inc. Common Stock Summary
Nasdaq / EQ
Healthcare
Biotechnology
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
AstraZeneca PLC Summary
Nasdaq / AZN
Healthcare
Drug Manufacturers - General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare EQ to other companies in the same or a similar industry.